Zhang, N., Zhang, G., Liu, N., Lin, W., Ji, S., Zheng, M., … Yang, S. (2017). A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models. Oncotarget, 8(67), 111495-111507. https://doi.org/10.18632/oncotarget.22847 (Original work published 2017)